Matthew Frank, MD, PhD, on Eliciting Response in Pretreated LBCL With CD22-Targeted CAR T Cells
August 15th 2023A presentation at EHA 2023 showed important safety and efficacy data with CD22 CAR T cells in heavily pretreated patients with large B-cell lymphoma and pointed to how this may shed light on sequencing in this field.
Kedar Kirtane, MD, on CAR T-Cell Agent A2B530 and Its Unique Approach to Solid Tumors
August 11th 2023The assistant member in the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center spoke about A2B530's mechanism of action and how it could represent a leap forward in the application of CAR T-cell agents for patients with solid tumors.